Breaking News

Tufts Study Boasts Growth in Big Pharma Biotech Products

November 14, 2013

Driven by new technologies, improved outcomes, and small molecule patent losses

The pharmaceutical industry, namely Big Pharma, has dramatically shifted its R&D focus from small molecule drugs to include a rapidly increasing number of biotechnology products, according to a new analysis from the Tufts Center for the Study of Drug Development.

Tufts CSDD found that biotech products accounted for 7% of revenue generated by the top 10 selling pharmaceutical-biotech products worldwide in 2001, and accounted for 71% in 2012. The transformation, according to Tufts CSDD director Kenneth I Kaitin, has been driven by new technologies enabling the development of products that improve disease outcomes and command high prices, as well as the patent expirations on many top-selling small molecule drugs.
 
Mr. Kaitin noted that novel technology platforms during the last three decades have spurred an extensive pipeline of products across a wide range of therapeutic areas. For example, in 1989 only 13 biotechnology products were commercially available and by 2012, that number had grown to 210.
 
The analysis reported also found that: the number of biotech products in clinical trials grew 155% in 11 years, from 355 in 2001 to 907 in 2012, with Big Pharma in 2012 engaged in 40% of all biotech products in development. Additionally, financing of biotech research increased from $10.5 billion in 2001 to $103 billion in 2012, and worldwide growth in product sales grew 353% between 2001 and 2012, from $36 billion to $163 billion.
 
The study was conducted by Ronald Evens, adjunct faculty and biotechnology consultant with Tufts CSDD.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important